Welcome to our dedicated page for Restart Life news (Ticker: NMLSF), a resource for investors and traders seeking the latest updates and insights on Restart Life stock.
Restart Life Sciences Corp. (OTC Pink: NMLSF) is a Canadian-based life sciences company listed on the CSE under the symbol HEAL. This news page aggregates company announcements and developments related to its health and wellness product portfolio, financing activities, and strategic transactions.
Recent company news highlights the introduction and development of functional wellness brands such as BrainQ™ and BrainBalls™, which are described as supporting cognitive health, brain wellness, and overall well-being. Updates also cover the company’s food technology and research initiatives, which are intended to support ingredient assessment, formulation performance, and future product development across its brands.
Investors and observers can follow news about Restart Life Sciences’ capital-raising efforts, including non-brokered private placements, warrant exercises, and loan financings. The company reports that these financings are intended to fund health food trials, research initiatives, potential acquisitions, and general working capital.
A key topic in recent announcements is a binding letter of intent to acquire Holy Crap Foods Inc. from Happy Belly Food Group Inc., subject to customary conditions and regulatory approvals. News items describe how this proposed acquisition would add the Holy Crap brand portfolio and a co-packer production facility in British Columbia, supporting vertical integration and providing a platform for Restart Life Sciences’ own product lines.
By reviewing this news feed, readers can track how Restart Life Sciences communicates its progress on product launches, research programs, proposed acquisitions, and financing milestones within the health and wellness and functional food sectors.
Nova Mentis Life Science Corp. (NMLSF) has entered into an intellectual property conveyance agreement with Ludwig Enterprises Inc. and Dr. Marvin S. Hausman. NOVA will assign its mRNA Neuro Panel and Serotonin Assay intellectual property to Ludwig. In exchange, Hausman will forgive NOVA's $245,712 debt, and Ludwig will issue 750,000 restricted common shares to NOVA. Additionally, NOVA will receive a 10-year royalty of 2.5% on revenue up to $245,712 and 5% thereafter from the Property's commercialization.
NOVA's Health Canada Phase 2a clinical trial for Fragile X Syndrome has faced recruitment challenges, with no candidates meeting enrollment requirements. The company's Board is actively seeking new business opportunities in the Life Sciences sector to create shareholder value.
Summary not available.
Summary not available.
Summary not available.
Wellbeing Digital Sciences Inc. (OTC: KONEF) announces the recruitment of participants for a pioneering clinical trial examining the effects of psilocybin on adults with fragile X syndrome (FXS). Conducted by its subsidiary KGK Sciences, the 28-day Phase IIA study is the first authorized by Health Canada allowing take-home psilocybin dosing. The study, set to treat its first participant in Q2 2023, aims to evaluate the safety and efficacy of Nova Mentis’ psilocybin drug (NM-1001) in a controlled environment, using advanced diagnostic technologies. Preliminary results are expected later this year, highlighting significant potential for psilocybin therapy in addressing unmet medical needs related to FXS.
Wellbeing Digital Sciences Inc. (KONEF, NMLSF) has announced that its subsidiary, KGK Sciences Inc., gained IRB approval in Canada to conduct a groundbreaking Phase IIA clinical trial. This study will test the efficacy of psilocybin on adults with fragile X syndrome (FXS), the leading genetic cause of autism spectrum disorder (ASD). The trial is part of a partnership with Nova Mentis Life Science Corp., aiming to assess psilocybin's impact on cognitive and behavioral symptoms. Patient recruitment is expected to begin this year. Notably, Health Canada has granted special permission for participants to take the drug home, marking a significant milestone in clinical research. This trial supports Nova's ongoing efforts to improve treatment options for FXS patients, following their FDA Orphan Drug designation received in 2021.
Wellbeing Digital Sciences Inc. (KONEF, NMLSF) announces its subsidiary, KGK Sciences, has received a Section 56 exemption to proceed with a Phase IIA clinical trial evaluating microdose psilocybin therapy for fragile X syndrome (FXS). This trial aims to study cognitive and behavioral symptoms linked to FXS, a major genetic cause of autism spectrum disorder. The study is significant as it represents a pioneering approach in this area, supported by a No Objection Letter from Health Canada. With the production of cGMP synthetic psilocybin underway, the trial seeks to enhance understanding of psilocybin's therapeutic potential, with participant recruitment starting in early 2023.
Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences has received approval from
Wellbeing Digital Sciences Inc. has announced that its subsidiary KGK Sciences submitted a clinical trial application for a Phase IIa study testing the efficacy of psilocybin in treating cognitive and behavioral symptoms associated with Fragile X Syndrome (FXS). The trial, sponsored by Nova Mentis Life Science Corp., will assess a 1.5 mg microdose of psilocybin and is expected to begin in early 2023 pending Health Canada's approval. This study marks a significant milestone as the first human trial using psilocybin for FXS.